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Reflections
 
1. General overview on breast cancer treatments
Breast cancer ranks fifth in cancer-related deaths among women. Therefore, the selection of 
systemic and local treatments influences the prognosis. They show different signal pathway 
and genetic differentiation. Besides ER, PR, and HER-2 receptor levels used in practice, cyto-
keratin, EGFR, germ line mutations, and mesenchymal markers currently bring many treat-
ment approaches into question. This shows the presence of factors that have not yet been fully 
understood. Hence, as new pathways, mutations, and different chemotherapeutic agents gain 
currency in the ongoing follow-up of each patient, clinicians are alienated from the standard 
treatment approach. In this chapter, local treatment options, early and advanced breast can-
cer treatments, drug resistance factors, alternative treatments, and palliative care have been 
addressed.
1.1. Local and systemic therapies
Breast cancer has been described in a sequential algorithm based on progressive disease 
course, beginning from neoadjuvant treatments. Approach to breast cancer as a systemic dis-
ease starting from the diagnosis phase extends the life span of the patients as well as increases 
the success rate of local treatments such as surgery and radiotherapy and decreases the toxic-
ity. Although neoadjuvant treatments have no effect on local control, they cause a decrease in 
radiotherapy-administered volumes. The eradication of micrometastases along with pCR has 
a prognostic importance.
Nowadays, classical mastectomy is alienated by the options of oncoplastic surgery. The side 
effects of silicone implants and expanders used, mesh and autologous tissue reconstructions 
have been enriched with patient images.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The prognostic factors such as lymph node, grade, tumor volume, histological type, recep-
tor status, Ki 67-index are important in early and local advanced breast cancer. Genetic risk 
assessment such as HR+ mammaprint, Oncotype DX, PAM-50 Prosigna in early breast cancer 
determines chemotherapy or hormonotherapy options. The effects and side effect profiles of 
preferred chemotherapy regimens were compared by meta-analysis and phase III trials con-
ducted by NSABP B-36, Early Breast Cancer Trialists’ Collaborative Group and their contribu-
tion to life span were discussed. Based on the SOFT and TEXT studies, the alternatives and 
usage periods of hormotherapy have been updated. In addition to conservative treatments, 
bisphosphonates recommended by ASCO have also been included in the adjuvant treatment.
Clinical trials like PALOMA-2, MONALEESA-2, MONARCHES-3, and MONALEESA-7 are 
important guidelines for hormone receptor-positive metastatic breast cancers. The use of 
CDK4/6 inhibitors in hormone-resistance tumors is an alternative to chemotherapeutics and 
antiestrogenic agents. In this chapter, phase II–III studies were compared and documented 
under the corresponding title.
Triple-negative breast cancers account for 15–20% of all breast cancers. The poor prognosis, 
drug resistance, genetic heterogeneity of triple-negative breast carcinomas and absence of a 
standard treatment regimen reduce the expected efficacy of chemotherapy. Platinum-based 
regimens particularly affect the calpain-1 pathway in the endoplasmic reticulum by the DNA 
damage and apoptosis they cause. This is an important prognostic factor. An increase in the 
MDA-MB-231 level and a decrease in the MCF-7, BT-474 proteins give a metastatic pattern 
to the cancer cells. These lead to aggressiveness in the biological characteristics of the tumor 
and resistance to chemotherapy drugs. In addition to platinum-based treatments, the use 
of anthracycline and taxanes provides a high rate of pCR, but also causes high recurrence 
rates during 1–3 year follow-ups. This paradox has still not been clarified. PD-L1, PI3K/AKT/
mTOR, histone deacetylase, PARP inhibitors that have recently been brought forward are a 
few of antiangiogenic treatment options. Antiangiogenic drugs take effect through the angio-
genesis induction mechanism of HIF-1 alpha gene. In the study mentioned in this chapter, it 
was emphasized that the HIF-1 alpha gene would increase the metastasis potential of tumor 
volume, unlike the subtype of tumor. Therefore, in addition to anthracyclines and taxanes, 
platinum-based chemotherapies also continue to be relevant.
Liquid biopsies, which have been started to be used in the treatment recently, help detect the 
tumor cells extravasated into the blood or lymphatic system. The CellSearch™ system helps 
diagnose by a rate of 20–30% in patients with early breast cancer. It is a leading biomarker in 
the monitoring of the treatment of the disease.
1.2. Alternative therapies
Dietary bacteria such as polyphenols, genistein, lactospirae, ruminococcaceae, Corynebacterium, 
staphylococcus, E. coli, actinomyces affect the immune system. Chemotherapeutic agents 
increase toxicity, fatigue, and infections such as cachexia, mucositis, and diarrhea by depress-
ing the immune flora. Supplementing the diet with pre- and probiotic agents with the purpose 
of reducing the therapeutic effects of drugs shortens the regeneration period of the cells.
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Photodynamic treatments and nanomedicine have fewer side effects compared with conven-
tional treatments. They increase the treatment tolerance by affecting the cancer cells in the 
target tissue. In the future, cancer vaccines, oncolytic virotherapy, immunotherapy options 
will take a part in the practice a lot more.
2. Palliative approaches
Palliative and psychological support should also be given in the treatment management. Level 
of education, proximity, and level of love between patient and family, cultural structure of the 
society and strength of religious values, success of the patient and his/her family in managing 
the disease process play an important role in the treatment management.
With “Breast cancer and Surgery,” a broad perspective was presented to patients with breast 
cancer in this chapter. Up-to-date information was provided to most clinicians and physi-
cians in the training period. Algorithms to be followed from the diagnosis phase to the treat-
ment and follow-up period of the disease are expressed in a certain manner. I believe that the 
“IntechOpen” series will be an important reference guide.
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